Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases

Inflamm Bowel Dis. 2023 May 2;29(5):830-833. doi: 10.1093/ibd/izac164.
No abstract available

Keywords: Crohn’s disease; dose escalation; inflammatory bowel disease; loss of response; optimization; ulcerative colitis; ustekinumab.

Plain language summary

In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both achieving and maintaining clinical remission for >40% of inflammatory bowel disease patients for up to 24 months.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colitis, Ulcerative*
  • Crohn Disease*
  • Humans
  • Inflammatory Bowel Diseases*
  • Remission Induction
  • Treatment Outcome
  • Ustekinumab

Substances

  • Ustekinumab